Healthy Skepticism Library item: 11294
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Grinols EL, Henderson JW.
Replace pharmaceutical patents now.
Pharmacoeconomics 2007; 25:(5):355-63
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=PubMed&Cmd=ShowDetailView&TermToSearch=17488135&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
Abstract:
Pharmaceutical patents are anachronistic holdovers from an era in which modern economic understanding and tax tools were unavailable. Superior mechanisms lie somewhere between a first best pricing solution for the entire economy at one extreme and the current arrangements at the other. We discuss the economics of suggested alternatives and suggest that the intertemporal bounty is the best way to meet the multiple objectives of immediate distribution at marginal cost pricing of newly innovated patented drugs and easily administered, efficient inducement to continued innovation. The intertemporal bounty prevents the expansion of monopoly power resulting from co-pay or -insurance provisions common to modern prescription drug plans.
Keywords:
MeSH Terms:
Drug Industry/economics*
Legislation, Drug/trends
Models, Economic
Patents/legislation & jurisprudence*
Pharmaceutical Preparations/economics*
Research
Substances:
Pharmaceutical Preparations
